Announcement PDF ASX Announcement Appendix 3Y-Dr Bill Garner 11 March 2020 – The Board of Race Oncology Limited (ASX: RAC) authorised the sale of 4,000,000 fully paid ordinary shares by Dr Bill Garner on Friday 6 March 2020 at a price of $0.30 per share. This sale will enable Merchant Opportunities Fund to become a significant holder in the Company while avoiding unnecessary dilution to shareholders. The Board is fully committed to minimising shareholder dilution at all times and continues to strengthen the Company’s shareholder base by attracting strategic, long term institutional investors, such as the Merchant Opportunities Fund. The Appendix 3Y is attached. - ENDS - About Race Oncology (RAC: ASX) Race Oncology (RAC) is a drug development biotech with a Phase II cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020. Release authorised by: Media contact: Peter Molloy, Managing Director Heidi Cuthbert plmolloy@raceoncology.com +61 411 272 366 heidi.cuthbert@multiplier.com.au Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538 Race Oncology Limited ABN 61 149 318 749 Registered office: L40, 140 William St, Melbourne VIC 3004 www.raceoncology.com Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Race Oncology Limited ABN 61 149 318 749 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director William James Garner Date of last notice 26 November 2019 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest 1. 2. Direct Indirect Nature of indirect interest (including registered holder) 2. Citicorp Nominees Pty Ltd – Beneficial Interest Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 6 March 2020 No. of securities held prior to change 1. 17,705,078 Ordinary Shares 757,575 Options exercisable at $0.099, expiring 31/08/2021 1,000,000 Options exercisable at $0.25, expiring 25/11/2021 2. 225,000 Ordinary Shares Class Ordinary Shares Number acquired Nil Number disposed 1. 4,000,000 Value/Consideration includes brokerage/gst $1,194,000 Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change 1. 13,705,078 Ordinary Shares 757,575 Options exercisable at $0.099, expiring 31/08/2021 1,000,000 Options exercisable at $0.25, expiring 25/11/2021 2. 225,000 Ordinary Shares Nature of change Off-market transaction – sale to strategic investor. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to N/A which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No. above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. Appendix 3Y Page 2